RLMD Logo

Relmada Therapeutics, Inc. (RLMD) 

NASDAQ$0.2649-0.03 (-10.11%)
Market Cap
$8.95M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
170 of 917
Rank in Industry
103 of 522

RLMD Insider Trading Activity

RLMD Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$642,8458100
Sells
$000

Related Transactions

TRAVERSA SERGIOChief Executive Officer3$395,1150$0$395,115
Shenouda MagedChief Financial Officer3$149,7010$0$149,701
Kelly Paul Edwarddirector1$64,7500$0$64,750
CASAMENTO CHARLES Jdirector1$33,2800$0$33,280

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Insider Activity of Relmada Therapeutics, Inc.

Over the last 12 months, insiders at Relmada Therapeutics, Inc. have bought $642,845 and sold $0 worth of Relmada Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Relmada Therapeutics, Inc. have bought $484,608 and sold $1.99M worth of stock each year.

Highest buying activity among insiders over the last 12 months: TRAVERSA SERGIO (Chief Executive Officer) — $395,115. Shenouda Maged (Chief Financial Officer) — $149,701. Kelly Paul Edward (director) — $64,750.

The last purchase of 51,407 shares for transaction amount of $153,707 was made by TRAVERSA SERGIO (Chief Executive Officer) on 2024‑09‑11.

List of Insider Buy and Sell Transactions, Relmada Therapeutics, Inc.

2024-09-11PurchaseTRAVERSA SERGIOChief Executive Officer
51,407
0.1813%
$2.99$153,707-40.39%
2024-09-11PurchaseShenouda MagedChief Financial Officer
24,120
0.0839%
$2.95$71,154-40.39%
2024-09-10PurchaseTRAVERSA SERGIOChief Executive Officer
33,014
0.1071%
$2.75$90,789-35.93%
2024-09-10PurchaseShenouda MagedChief Financial Officer
21,118
0.068%
$2.73$57,652-35.93%
2024-09-09PurchaseTRAVERSA SERGIOChief Executive Officer
55,579
0.1789%
$2.71$150,619-35.33%
2024-09-09PurchaseKelly Paul Edwarddirector
25,000
0.0769%
$2.59$64,750-35.33%
2024-09-09PurchaseShenouda MagedChief Financial Officer
8,194
0.0248%
$2.55$20,895-35.33%
2024-09-09PurchaseCASAMENTO CHARLES Jdirector
13,000
0.0395%
$2.56$33,280-35.33%
2024-01-31PurchaseTRAVERSA SERGIOChief Executive Officer
27,460
0.0923%
$4.00$109,752-15.27%
2024-01-31PurchaseEnce ChuckCA and CO
13,670
0.0466%
$4.05$55,429-15.27%
2024-01-31PurchaseShenouda MagedChief Financial Officer
6,875
0.0235%
$4.06$27,943-15.27%
2024-01-30PurchaseTRAVERSA SERGIOChief Executive Officer
40,999
0.1345%
$3.90$159,949-16.08%
2024-01-30PurchaseShenouda MagedChief Financial Officer
15,000
0.0491%
$3.89$58,323-16.08%
2024-01-30PurchaseEnce ChuckCA and CO
14,500
0.0471%
$3.87$56,053-16.08%
2024-01-29PurchaseTRAVERSA SERGIOChief Executive Officer
31,541
0.1037%
$3.71$117,036-9.95%
2024-01-29PurchaseShenouda MagedChief Financial Officer
10,800
0.035%
$3.65$39,450-9.95%
2024-01-29PurchaseEnce ChuckCA and CO
10,800
0.0349%
$3.65$39,438-9.95%
2023-05-23PurchaseO'Gorman CedricChief Medical Officer
10,000
0.0338%
$3.18$31,800+0.32%
2022-12-08PurchaseTRAVERSA SERGIOChief Executive Officer
55,250
0.1801%
$2.10$115,804+37.79%
2022-06-30SaleTRAVERSA SERGIOChief Executive Officer
4,068
0.0131%
$18.32$74,526-73.16%
Total: 88
*Gray background shows transactions not older than one year

Insider Historical Profitability

7.52%
TRAVERSA SERGIOChief Executive Officer
384024
1.2727%
$113,939.92914<0.0001%
Kelly Paul Edwarddirector
212295
0.7036%
$62,987.93611+80.43%
Shenouda MagedChief Financial Officer
88335
0.2928%
$26,208.99914<0.0001%
CASAMENTO CHARLES Jdirector
13000
0.0431%
$3,857.10215
SETH SANDESHdirector
123258
0.4085%
$36,570.6520
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$18,881,323
88
-48.96%
$6.99M
$1,241,605
44
-21.46%
$8.75M
$523,320
24
94.37%
$6.98M
$746,223
23
-7.24%
$6.79M
$86,569,038
18
-12.64%
$9.15M

RLMD Institutional Investors: Active Positions

Increased Positions17+15.74%787,351+6.35%
Decreased Positions48-44.44%5M-38.44%
New Positions7New164,940New
Sold Out Positions28Sold Out3MSold Out
Total Postitions77-28.7%8M-32.08%

RLMD Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Franklin Resources Inc$387.003.95%1.3M00%2024-12-31
Vanguard Group Inc$373.003.81%1.26M00%2024-12-31
Acadian Asset Management Llc$365.003.72%1.23M+41,476+3.5%2024-12-31
Blackrock, Inc.$176.001.8%593,326+25,446+4.48%2024-12-31
Palo Alto Investors Lp$147.001.5%495,146-237,254-32.39%2024-12-31
Geode Capital Management, Llc$90.000.92%302,838-1,664-0.55%2024-12-31
Deutsche Bank Ag$67.000.68%224,84600%2024-12-31
Ubs Group Ag$64.000.65%215,140+88,755+70.23%2024-12-31
Advisorshares Investments Llc$62.000.64%210,068+141,540+206.54%2024-12-31
Bank Of America Corp /De/$61.000.63%206,657<10%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.